We are monitoring the impact of COVID-19 & Recession alarm on Latin America Parkinson’s Disease Treatment Market Get in touch with us for detailed analysis Know More

Know More

Share on

Latin America Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (Brazil, Mexico, Argentina, Chile & Rest of Latin America) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 7153
Pages: 145

The size of the Latin America Parkinson’s Disease Treatment Market was worth USD 0.54 billion in 2022 and is estimated to be growing at a CAGR of 5.98%, to reach USD 0.72 billion by 2027.

The increasing prevalence of Parkinson's disease (PD) and the rapid growth in the geriatric population with long expectancy, which is more susceptible to neurodegenerative diseases, are the key factors for developing the Latin American Parkinson’s disease treatment market. In addition, the growing awareness of the available treatment alternatives is also driving the market's growth. Parkinson's disease is more common in men than in women, according to the Parkinson Foundation. A higher incidence was found in men with an approximately 1.55 times higher risk than women. People over the age of 60 are mostly affected by this disease.

Although, there is no permanent cure available to treat Parkinson's disease. Medication, along with other therapies such as exercise, can help relieve some of the symptoms of Parkinson's disease. Drugs such as the combination of levodopa therapy, dopamine agonists, cholinesterase inhibitors, and others are used to treat the various symptoms associated with the disease. Currently, combination therapy with levodopa is highly recommended as it is used to treat the motor symptoms of this disease. Even COMT inhibitors are gaining popularity with co-therapeutic agents for maximum effectiveness.

In addition, various innovations in treatment methods, such as the development of neurostimulation tools, gene therapy, and neural transplantation procedures, act as other growth factors anticipated to impact the market positively. There are significant improvements in healthcare infrastructure coupled with extensive research and development (R&D) activities supported by governments and non-profit organizations to develop promising product portfolios.

However, the easy availability of alternative treatments and limited effectiveness of the treatment options slows down the growth of the Parkinson's disease treatment market in Latin America. Moreover, various side effects of the drugs may jeopardize market growth in the years to come. For example, impulsive and compulsive behaviors are possible side effects found with some medications. The expiration of the patent on key brand-name drugs will also limit the growth of the Latin American Parkinson's disease treatment market.

This research report on Latin American Parkinson’s disease treatment market has been segmented and sub-segmented into the following categories:

By Drug Class: 

  • Dopamine Receptor Antagonists
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics
  • Other Drug Classes

By Distribution Channels: 

  • Retailer Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Patient Care Setting:

  • Clinics
  • Hospitals 

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Peru
  • Rest of Latin America

Geographically, Brazil accounted for the largest share of the Latin America Parkinson's disease treatment market in 2022, followed by Argentina with a substantial market share. Factors such as the high awareness among the elderly population increased research funding and grants, favorable government policies, a high prevalence of Parkinson's disease, will support the regional markets in these regions. According to the latest WHO data released, deaths from Parkinson's disease in Brazil reached 3,980, or 0.38% of all deaths, and a total of 240 incident PD cases have been identified. Meanwhile, the gross incidence was recorded at 31.24/100,000 people, with a prevalence of 395/100 000 in Mexico over 40 years old. Based on recent data, the male / female ratio was reported at 1.32 in the Mexican population.

Other factors such as the rapidly growing geriatric population, promising clinical products, and favorable reimbursement policies are expected to drive the regional markets in Argentina, Mexico, Peru, and Columbia.

KEY MARKET PLAYERS:

Some of the major players in the market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 Brazil                             

                6.3 Mexico                         

                6.4 Rest of Latin America                             

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Parkinson’s Disease Treatment Market, By Drug Class, From 2022 - 2027 ( USD Billion )
  2. Latin America Dopamine Receptor Antagonists Market, By Region, From 2022 - 2027 ( USD Billion )
  3. Latin America Mono Amine Oxidase Inhibitors Market, By Region, From 2022 - 2027 ( USD Billion )
  4. Latin America Carbidopa Market, By Region, From 2022 - 2027 ( USD Billion )
  5. Latin America Anticholinergics  Market, By Region, From 2022 - 2027 ( USD Billion )
  6. Latin America Other Drug Classes Market, By Region, From 2022 - 2027 ( USD Billion )
  7. Latin America Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
  8. Latin America Retailer Pharmacies Market, By Region, From 2022 - 2027 ( USD Billion )
  9. Latin America Hospital Pharmacies  Market, By Region, From 2022 - 2027 ( USD Billion )
  10. Latin America Online Pharmacies Market, By Region, From 2022 - 2027 ( USD Billion )
  11. Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
  12. Latin America Clinics  Market, By Region, From 2022 - 2027 ( USD Billion )
  13. Latin America Hospitals Market, By Region, From 2022 - 2027 ( USD Billion )
  14. Brazil Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
  15. Brazil Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
  16. Brazil Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
  17. Argentina Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
  18. Argentina Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
  19. Argentina Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
  20. Mexico Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
  21. Mexico Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
  22. Mexico Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
  23. Rest of Latin America Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
  24. Rest of Latin America Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
  25. Rest of Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample